Patient Relevant Outcomes Improvement Program in High Risk Hormone Receptor Positive (HR+) Breast Cancer

Institut fuer Frauengesundheit200 enrolled

Overview

The goal of this observational study is to evaluate how persistently patients with high-risk early breast cancer take abemaciclib 6 months after therapy start. To this end, researchers will perform a retrospective analysis of therapy data.

Study Type

OBSERVATIONAL

Enrollment

200

Conditions

HR+/HER2- Early Breast Cancer

Eligibility

Sex: FEMALEMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Femal patients age 18 or older at time of informed consent * Confirmed diagnosis of HR+/HER2- early breast cancer (no distant metastasis) * Prescribed abemaciclib therapy according to the Summary of Product Characteristics (SmPC) * Abemaciclib therapy occured between January 1st, 2023 and June 30th, 2025 Exclusion Criteria: * Locally advanced or metastatic breast cancer * Male patients * Patients with contraindication(s) for abemaciclib therapy according to SmPC

Locations (1)

Department of Obstetrics and Gynaecology, Uniklinikum Erlangen

Erlangen, Bavaria, Germany

RECRUITING

Outcomes

Primary Outcomes

Abemaciclib persistence rate

Abemaciclib persistence rate (defined as ongoing abemaciclib therapy)

Time frame: 6 months after therapy start

Central Contacts

Sponsor's study office

CONTACT

+49 15739466438 studien@ifg-erlangen.de

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.